These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
284 related articles for article (PubMed ID: 31462766)
41. Differential reinforcement learning responses to positive and negative information in unmedicated individuals with depression. Reinen JM; Whitton AE; Pizzagalli DA; Slifstein M; Abi-Dargham A; McGrath PJ; Iosifescu DV; Schneier FR Eur Neuropsychopharmacol; 2021 Dec; 53():89-100. PubMed ID: 34517334 [TBL] [Abstract][Full Text] [Related]
42. Rhodiola rosea versus sertraline for major depressive disorder: A randomized placebo-controlled trial. Mao JJ; Xie SX; Zee J; Soeller I; Li QS; Rockwell K; Amsterdam JD Phytomedicine; 2015 Mar; 22(3):394-9. PubMed ID: 25837277 [TBL] [Abstract][Full Text] [Related]
43. Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder - possible role for methoxyindole pathway. Zhu H; Bogdanov MB; Boyle SH; Matson W; Sharma S; Matson S; Churchill E; Fiehn O; Rush JA; Krishnan RR; Pickering E; Delnomdedieu M; Kaddurah-Daouk R; PLoS One; 2013; 8(7):e68283. PubMed ID: 23874572 [TBL] [Abstract][Full Text] [Related]
44. St John's wort (Hypericum perforatum) versus sertraline and placebo in major depressive disorder: continuation data from a 26-week RCT. Sarris J; Fava M; Schweitzer I; Mischoulon D Pharmacopsychiatry; 2012 Nov; 45(7):275-8. PubMed ID: 22592504 [TBL] [Abstract][Full Text] [Related]
45. Amygdala Reactivity to Emotional Faces in the Prediction of General and Medication-Specific Responses to Antidepressant Treatment in the Randomized iSPOT-D Trial. Williams LM; Korgaonkar MS; Song YC; Paton R; Eagles S; Goldstein-Piekarski A; Grieve SM; Harris AW; Usherwood T; Etkin A Neuropsychopharmacology; 2015 Sep; 40(10):2398-408. PubMed ID: 25824424 [TBL] [Abstract][Full Text] [Related]
46. Brain functional alterations observed 4-weekly in major depressive disorder following antidepressant treatment. Yamagata B; Yamanaka K; Takei Y; Hotta S; Hirano J; Tabuchi H; Mimura M J Affect Disord; 2019 Jun; 252():25-31. PubMed ID: 30959413 [TBL] [Abstract][Full Text] [Related]
47. Examining raphe-amygdala structural connectivity as a biological predictor of SSRI response. Pillai RLI; Huang C; LaBella A; Zhang M; Yang J; Trivedi M; Weissman M; McGrath P; Fava M; Kurian B; Cooper C; McInnis M; Oquendo MA; Pizzagalli DA; Parsey RV; DeLorenzo C J Affect Disord; 2019 Sep; 256():8-16. PubMed ID: 31158720 [TBL] [Abstract][Full Text] [Related]
48. Sertraline in children and adolescents with major depressive disorder. Donnelly CL; Wagner KD; Rynn M; Ambrosini P; Landau P; Yang R; Wohlberg CJ J Am Acad Child Adolesc Psychiatry; 2006 Oct; 45(10):1162-1170. PubMed ID: 17003661 [TBL] [Abstract][Full Text] [Related]
50. Striatal dopamine D2/3 receptor-mediated neurotransmission in major depression: Implications for anhedonia, anxiety and treatment response. Peciña M; Sikora M; Avery ET; Heffernan J; Peciña S; Mickey BJ; Zubieta JK Eur Neuropsychopharmacol; 2017 Oct; 27(10):977-986. PubMed ID: 28870407 [TBL] [Abstract][Full Text] [Related]
51. The relationship of MRI subcortical hyperintensities to treatment response in a trial of sertraline in geriatric depressed outpatients. Salloway S; Boyle PA; Correia S; Malloy PF; Cahn-Weiner DA; Schneider L; Krishnan KR; Nakra R Am J Geriatr Psychiatry; 2002; 10(1):107-11. PubMed ID: 11790641 [TBL] [Abstract][Full Text] [Related]
52. Heart rate variability as a biomarker of anxious depression response to antidepressant medication. Kircanski K; Williams LM; Gotlib IH Depress Anxiety; 2019 Jan; 36(1):63-71. PubMed ID: 30311742 [TBL] [Abstract][Full Text] [Related]
53. Comparing the Effects of Sertraline with Duloxetine for Depression Severity and Symptoms: A Double-Blind, Randomized Controlled Trial. Mowla A; Dastgheib SA; Razeghian Jahromi L Clin Drug Investig; 2016 Jul; 36(7):539-43. PubMed ID: 27071759 [TBL] [Abstract][Full Text] [Related]
54. Dopamine Release in Antidepressant-Naive Major Depressive Disorder: A Multimodal [ Schneier FR; Slifstein M; Whitton AE; Pizzagalli DA; Reinen J; McGrath PJ; Iosifescu DV; Abi-Dargham A Biol Psychiatry; 2018 Oct; 84(8):563-573. PubMed ID: 30041971 [TBL] [Abstract][Full Text] [Related]
55. A Randomized Placebo-Controlled Trial of Omega-3 and Sertraline in Depressed Patients With or at Risk for Coronary Heart Disease. Carney RM; Freedland KE; Rubin EH; Rich MW; Steinmeyer BC; Harris WS J Clin Psychiatry; 2019 Jun; 80(4):. PubMed ID: 31163106 [TBL] [Abstract][Full Text] [Related]
56. A placebo-controlled, randomized withdrawal study of sertraline for major depressive disorder in Japan. Kamijima K; Burt T; Cohen G; Arano I; Hamasaki T Int Clin Psychopharmacol; 2006 Jan; 21(1):1-9. PubMed ID: 16317311 [TBL] [Abstract][Full Text] [Related]
57. Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial. Costi S; Morris LS; Kirkwood KA; Hoch M; Corniquel M; Vo-Le B; Iqbal T; Chadha N; Pizzagalli DA; Whitton A; Bevilacqua L; Jha MK; Ursu S; Swann AC; Collins KA; Salas R; Bagiella E; Parides MK; Stern ER; Iosifescu DV; Han MH; Mathew SJ; Murrough JW Am J Psychiatry; 2021 May; 178(5):437-446. PubMed ID: 33653118 [TBL] [Abstract][Full Text] [Related]
58. Major depression in mothers predicts reduced ventral striatum activation in adolescent female offspring with and without depression. Sharp C; Kim S; Herman L; Pane H; Reuter T; Strathearn L J Abnorm Psychol; 2014 May; 123(2):298-309. PubMed ID: 24886004 [TBL] [Abstract][Full Text] [Related]